MONTREAL, Feb. 15, 2022 /CNW Telbec/ - Lumiera Health
Inc. (TSXV: NHP) (the "Company" or
"Lumiera "), a company specializing in the development
and commercialization of evidence-based botanical products, is
pleased to announce the signing of a binding term sheet with Pain
Level LLC, a NY-based broker. Pain Level LLC will be representing
the company's Awaye™ pain relief product in the Northeastern US
market. In addition to managing sales initiatives and the
distribution network, the group will be responsible for executing
the advertising and marketing programs in their territory, which
covers New York, New Jersey and Connecticut.
This agreement represents one of Lumiera's important milestones
in its growth strategy and represents the first step towards
expanding outside of Canada.
"Awaye™ is a great product that launched Direct to Consumer in
April of last year. We have received very positive feedback from
consumers that are using Awaye™ and are seeing strong month over
month growth. Based on Awaye™'s success, we are now driving
Retail Distribution and are very happy to be working with Jerry and
the new Pain Level team to launch Awaye™ in New York, New
Jersey and Connecticut as
the revenue potential is outstanding" says Carlos Ponce, CEO of Lumiera.
"As a team we are really excited. The market potential for
Awaye™ is incredible; an effective, natural pain relief cream is
very much on trend and we are looking forward to driving
distribution and sales of Awaye™ amongst our retail network and
making it a success across the tri-State area" says Jerry Safran, co-managing director of the newly
formed Pain Level LLC.
The binding term sheet set the material terms towards the
signing of a final agreement, which should be completed on or
before February 28, 2022.
About Awaye™
Awaye™ provides a new generation of relief from acute and
chronic pain by exploiting the CB2 receptors of the endocannabinoid
system, the body's built in pain and inflammation defense system.
Awaye™ is a unique Health Canada approved topical cream that
provides relief from pain through complimentary mechanisms of
action not found in any other product currently available on the
market.
For more information about Awaye™ products, visit www.awaye.ca
About Pain Level LLC
Pain Level LLC is led by Jerry
Safran. Mr. Safran has 20+ years' experience building retail
brands in the grocery & supplements sector, and has developed
deep relationships with major super-market chains, big box
retailers and pharmacies. Jerry is joined by Daniel Katcher, a proven leader for 25 years in
commercial sales. Deborah Kogan
Eilender, a veteran brand-builder in the healthcare industry
and former Consumer Marketing leader at one of the largest global
pharmaceutical companies will provide marketing expertise for Pain
Level LLC.
About Lumiera Health
Lumiera specializes in the development and commercialization of
consumer products for the natural health industry. The Company
sells herbal tonics and natural supplements through its Holizen
Laboratories division, with a diverse portfolio including a line of
innovative sleep aids. The Company is also commercializing a unique
topical product line acting on the endocannabinoid system, without
the use of cannabis, that provides an innovative solution for
chronic pain and inflammation. A pioneer in the natural health
innovation space, the Lumiera brand is rooted in the core values of
science, nature and compassion. Our goal is to make people's
lives better by developing natural health and wellness products
that are effective, safe and trustworthy.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2020,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions were
applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
SOURCE Lumiera Health Inc.